Lacosamide Ucb (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilises neuronal membranes and reduces repetitive firing. It also binds to the protein CRMP‑2, influencing neuronal differentiation and axonal growth, together limiting seizure propagation.

The appropriate dose of Lacosamide Ucb is determined by the prescribing clinician based on the individual’s clinical condition, age, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation and binding CRMP‑2—differs from many older antiseizure medicines that target fast inactivation. This can offer an alternative for patients who have inadequate response or intolerable side effects with other agents, though individual response varies.

Store Lacosamide Ucb at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lacosamide Ucb is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation or atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, and significant liver enzyme elevations. Patients should seek immediate medical attention if any of these occur.

Lacosamide Ucb is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients, and it should be avoided in individuals with pre‑existing severe cardiac conduction disorders unless closely monitored by a cardiologist.